APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte Macrophage Colony Stimulating Factor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Granulocyte Macrophage Colony Stimulating Factor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025192 pages

Choose your research edition.

Industry ResearchGranulocyte Macrophage Colony Stimulating Factor Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte Macrophage Colony Stimulating Factor Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Granulocyte Macrophage Colony Stimulating Factor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte Macrophage Colony Stimulating Factor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte Macrophage Colony Stimulating Factor Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Granulocyte Macrophage Colony Stimulating Factor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Granulocyte Macrophage Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulocyte Macrophage Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocyte Macrophage Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Granulocyte Macrophage Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Granulocyte Macrophage Colony Stimulating Factor include Takeda Pharmaceutical Co Ltd, GlaxoSmithKline Plc, Amgen Inc, Sillajen Biotherapeutics, Morphotek Inc, Mologen AG, Humanigen Inc, Cold Genesys Inc and BriaCell Therapeutics Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Granulocyte Macrophage Colony Stimulating Factor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulocyte Macrophage Colony Stimulating Factor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulocyte Macrophage Colony Stimulating Factor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Granulocyte Macrophage Colony Stimulating Factor market size, projected growth trends, production technologies, key applications, and end-use industries.

Granulocyte Macrophage Colony Stimulating Factor Segment by Company

Takeda Pharmaceutical Co Ltd

GlaxoSmithKline Plc

Amgen Inc

Sillajen Biotherapeutics

Morphotek Inc

Mologen AG

Humanigen Inc

Cold Genesys Inc

BriaCell Therapeutics Corp

Aduro BioTech Inc

Granulocyte Macrophage Colony Stimulating Factor Segment by Type

CG-0070

Lenzilumab

Gimsilumab

MGN-1601

GSK-3196165

Others

Granulocyte Macrophage Colony Stimulating Factor Segment by Application

Solid Tumor

Kidney Cancer

Lymphoma

Lung Disease

Others

Granulocyte Macrophage Colony Stimulating Factor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte Macrophage Colony Stimulating Factor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte Macrophage Colony Stimulating Factor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte Macrophage Colony Stimulating Factor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Granulocyte Macrophage Colony Stimulating Factor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Granulocyte Macrophage Colony Stimulating Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Granulocyte Macrophage Colony Stimulating Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Granulocyte Macrophage Colony Stimulating Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Granulocyte Macrophage Colony Stimulating Factor Industry Trends Table 2. Granulocyte Macrophage Colony Stimulating Factor Industry Drivers Table 3. Granulocyte Macrophage Colony Stimulating Factor Industry Opportunities and Challenges Table 4. Granulocyte Macrophage Colony Stimulating Factor Industry Restraints Table 5. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Manufacturers Table 9. Global Granulocyte Macrophage Colony Stimulating Factor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Granulocyte Macrophage Colony Stimulating Factor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Granulocyte Macrophage Colony Stimulating Factor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Granulocyte Macrophage Colony Stimulating Factor Manufacturers, Product Type & Application Table 13. Global Granulocyte Macrophage Colony Stimulating Factor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Granulocyte Macrophage Colony Stimulating Factor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of CG-0070 Table 17. Major Manufacturers of Lenzilumab Table 18. Major Manufacturers of Gimsilumab Table 19. Major Manufacturers of MGN-1601 Table 20. Major Manufacturers of GSK-3196165 Table 21. Major Manufacturers of Others Table 22. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type (2021-2026) & (K Units) Table 24. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type (2027-2032) & (K Units) Table 25. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Type (2021-2026) Table 26. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Type (2027-2032) Table 27. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Type (2021-2026) & (K Units) Table 29. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Type (2027-2032) & (K Units) Table 30. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Type (2021-2026) Table 31. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Solid Tumor Table 33. Major Manufacturers of Kidney Cancer Table 34. Major Manufacturers of Lymphoma Table 35. Major Manufacturers of Lung Disease Table 36. Major Manufacturers of Others Table 37. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application (2021-2026) & (K Units) Table 39. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application (2027-2032) & (K Units) Table 40. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Application (2021-2026) Table 41. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Application (2027-2032) Table 42. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 43. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Application (2021-2026) & (K Units) Table 44. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Application (2027-2032) & (K Units) Table 45. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Application (2021-2026) Table 46. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Application (2027-2032) Table 47. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region (2021-2026) & (K Units) Table 49. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Region (2021-2026) Table 50. Global Granulocyte Macrophage Colony Stimulating Factor Sales Forecasted by Region (2027-2032) & (K Units) Table 51. Global Granulocyte Macrophage Colony Stimulating Factor Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Granulocyte Macrophage Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. North America Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 54. North America Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 55. Europe Granulocyte Macrophage Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Europe Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 57. Europe Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 58. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 60. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 61. South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 62. South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 63. South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 64. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Region (2021-2026) Table 68. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Region (2027-2032) Table 69. Takeda Pharmaceutical Co Ltd Company Information Table 70. Takeda Pharmaceutical Co Ltd Business Overview Table 71. Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 73. Takeda Pharmaceutical Co Ltd Recent Development Table 74. GlaxoSmithKline Plc Company Information Table 75. GlaxoSmithKline Plc Business Overview Table 76. GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 78. GlaxoSmithKline Plc Recent Development Table 79. Amgen Inc Company Information Table 80. Amgen Inc Business Overview Table 81. Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 83. Amgen Inc Recent Development Table 84. Sillajen Biotherapeutics Company Information Table 85. Sillajen Biotherapeutics Business Overview Table 86. Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 88. Sillajen Biotherapeutics Recent Development Table 89. Morphotek Inc Company Information Table 90. Morphotek Inc Business Overview Table 91. Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 93. Morphotek Inc Recent Development Table 94. Mologen AG Company Information Table 95. Mologen AG Business Overview Table 96. Mologen AG Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Mologen AG Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 98. Mologen AG Recent Development Table 99. Humanigen Inc Company Information Table 100. Humanigen Inc Business Overview Table 101. Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 103. Humanigen Inc Recent Development Table 104. Cold Genesys Inc Company Information Table 105. Cold Genesys Inc Business Overview Table 106. Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 108. Cold Genesys Inc Recent Development Table 109. BriaCell Therapeutics Corp Company Information Table 110. BriaCell Therapeutics Corp Business Overview Table 111. BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 113. BriaCell Therapeutics Corp Recent Development Table 114. Aduro BioTech Inc Company Information Table 115. Aduro BioTech Inc Business Overview Table 116. Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 118. Aduro BioTech Inc Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Granulocyte Macrophage Colony Stimulating Factor Distributors List Table 122. Granulocyte Macrophage Colony Stimulating Factor Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Granulocyte Macrophage Colony Stimulating Factor Product Image Figure 2. Global Granulocyte Macrophage Colony Stimulating Factor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulocyte Macrophage Colony Stimulating Factor Market Size (2021-2032) & (US$ Million) Figure 4. Global Granulocyte Macrophage Colony Stimulating Factor Sales (2021-2032) & (K Units) Figure 5. Global Granulocyte Macrophage Colony Stimulating Factor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Granulocyte Macrophage Colony Stimulating Factor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. CG-0070 Image Figure 9. Lenzilumab Image Figure 10. Gimsilumab Image Figure 11. MGN-1601 Image Figure 12. GSK-3196165 Image Figure 13. Others Image Figure 14. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Type (2021-2032) Figure 17. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Type (2021-2032) Figure 20. Solid Tumor Image Figure 21. Kidney Cancer Image Figure 22. Lymphoma Image Figure 23. Lung Disease Image Figure 24. Others Image Figure 25. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Application (2021-2032) Figure 28. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 29. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Application (2021-2032) Figure 31. North America Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. North America Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 33. U.S. Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Canada Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Mexico Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Europe Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 38. Germany Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. France Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 40. U.K. Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Italy Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 45. China Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Japan Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Korea Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 49. India Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Australia Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 53. Brazil Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. South Africa Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Turkey Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Argentina Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 58. UAE Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Egypt Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Chile Granulocyte Macrophage Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 61. Global Granulocyte Macrophage Colony Stimulating Factor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Granulocyte Macrophage Colony Stimulating Factor Revenue (2021-2032) & (US$ Million) Figure 64. North America Granulocyte Macrophage Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Granulocyte Macrophage Colony Stimulating Factor Revenue (2021-2032) & (US$ Million) Figure 66. Europe Granulocyte Macrophage Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Granulocyte Macrophage Colony Stimulating Factor Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Granulocyte Macrophage Colony Stimulating Factor Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • CG-0070
  • Lenzilumab
  • Gimsilumab
  • MGN-1601
  • GSK-3196165
  • Others
Applications
  • Solid Tumor
  • Kidney Cancer
  • Lymphoma
  • Lung Disease
  • Others
Companies covered
  • Takeda Pharmaceutical Co Ltd
  • GlaxoSmithKline Plc
  • Amgen Inc
  • Sillajen Biotherapeutics
  • Morphotek Inc
  • Mologen AG
  • Humanigen Inc
  • Cold Genesys Inc
  • BriaCell Therapeutics Corp
  • Aduro BioTech Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Granulocyte Macrophage Colony Stimulating Factor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Granulocyte Macrophage Colony Stimulating Factor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Granulocyte Macrophage Colony Stimulating Factor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Granulocyte Macrophage Colony Stimulating Factor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Granulocyte Macrophage Colony Stimulating Factor Market Dynamics
  1. 2.1 Granulocyte Macrophage Colony Stimulating Factor Industry Trends
  2. 2.2 Granulocyte Macrophage Colony Stimulating Factor Industry Drivers
  3. 2.3 Granulocyte Macrophage Colony Stimulating Factor Industry Opportunities and Challenges
  4. 2.4 Granulocyte Macrophage Colony Stimulating Factor Industry Restraints
3 Granulocyte Macrophage Colony Stimulating Factor Market by Manufacturers
  1. 3.1 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Manufacturers (2021-2026)
  3. 3.3 Global Granulocyte Macrophage Colony Stimulating Factor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Granulocyte Macrophage Colony Stimulating Factor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Granulocyte Macrophage Colony Stimulating Factor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Granulocyte Macrophage Colony Stimulating Factor Manufacturers, Product Type & Application
  7. 3.7 Global Granulocyte Macrophage Colony Stimulating Factor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Granulocyte Macrophage Colony Stimulating Factor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Granulocyte Macrophage Colony Stimulating Factor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Granulocyte Macrophage Colony Stimulating Factor Tier 1, Tier 2, and Tier 3
4 Granulocyte Macrophage Colony Stimulating Factor Market by Type
  1. 4.1 Granulocyte Macrophage Colony Stimulating Factor Type Introduction
  2. 4.1.1 CG-0070
  3. 4.1.2 Lenzilumab
  4. 4.1.3 Gimsilumab
  5. 4.1.4 MGN-1601
  6. 4.1.5 GSK-3196165
  7. 4.1.6 Others
  8. 4.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type
  9. 4.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Type (2021-2032)
  11. 4.2.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Type (2021-2032)
  12. 4.3 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Type
  13. 4.3.1 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Type (2021-2032)
  15. 4.3.3 Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Type (2021-2032)
5 Granulocyte Macrophage Colony Stimulating Factor Market by Application
  1. 5.1 Granulocyte Macrophage Colony Stimulating Factor Application Introduction
  2. 5.1.1 Solid Tumor
  3. 5.1.2 Kidney Cancer
  4. 5.1.3 Lymphoma
  5. 5.1.4 Lung Disease
  6. 5.1.5 Others
  7. 5.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application
  8. 5.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Application (2021-2032)
  10. 5.2.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Application (2021-2032)
  11. 5.3 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Application
  12. 5.3.1 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Application (2021-2032)
  14. 5.3.3 Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Application (2021-2032)
6 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region
  1. 6.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region (2021-2032)
  3. 6.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region (2021-2026)
  4. 6.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Granulocyte Macrophage Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Granulocyte Macrophage Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region
  1. 7.1 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region
  2. 7.1.1 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region (2021-2026)
  4. 7.1.3 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Region (2027-2032)
  5. 7.1.4 Global Granulocyte Macrophage Colony Stimulating Factor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Granulocyte Macrophage Colony Stimulating Factor Revenue (2021-2032)
  8. 7.2.2 North America Granulocyte Macrophage Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Granulocyte Macrophage Colony Stimulating Factor Revenue (2021-2032)
  11. 7.3.2 Europe Granulocyte Macrophage Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Granulocyte Macrophage Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Co Ltd
  2. 8.1.1 Takeda Pharmaceutical Co Ltd Company Information
  3. 8.1.2 Takeda Pharmaceutical Co Ltd Business Overview
  4. 8.1.3 Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Co Ltd Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 Amgen Inc
  14. 8.3.1 Amgen Inc Company Information
  15. 8.3.2 Amgen Inc Business Overview
  16. 8.3.3 Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  18. 8.3.5 Amgen Inc Recent Developments
  19. 8.4 Sillajen Biotherapeutics
  20. 8.4.1 Sillajen Biotherapeutics Company Information
  21. 8.4.2 Sillajen Biotherapeutics Business Overview
  22. 8.4.3 Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  24. 8.4.5 Sillajen Biotherapeutics Recent Developments
  25. 8.5 Morphotek Inc
  26. 8.5.1 Morphotek Inc Company Information
  27. 8.5.2 Morphotek Inc Business Overview
  28. 8.5.3 Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  30. 8.5.5 Morphotek Inc Recent Developments
  31. 8.6 Mologen AG
  32. 8.6.1 Mologen AG Company Information
  33. 8.6.2 Mologen AG Business Overview
  34. 8.6.3 Mologen AG Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Mologen AG Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  36. 8.6.5 Mologen AG Recent Developments
  37. 8.7 Humanigen Inc
  38. 8.7.1 Humanigen Inc Company Information
  39. 8.7.2 Humanigen Inc Business Overview
  40. 8.7.3 Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  42. 8.7.5 Humanigen Inc Recent Developments
  43. 8.8 Cold Genesys Inc
  44. 8.8.1 Cold Genesys Inc Company Information
  45. 8.8.2 Cold Genesys Inc Business Overview
  46. 8.8.3 Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  48. 8.8.5 Cold Genesys Inc Recent Developments
  49. 8.9 BriaCell Therapeutics Corp
  50. 8.9.1 BriaCell Therapeutics Corp Company Information
  51. 8.9.2 BriaCell Therapeutics Corp Business Overview
  52. 8.9.3 BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  54. 8.9.5 BriaCell Therapeutics Corp Recent Developments
  55. 8.10 Aduro BioTech Inc
  56. 8.10.1 Aduro BioTech Inc Company Information
  57. 8.10.2 Aduro BioTech Inc Business Overview
  58. 8.10.3 Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  60. 8.10.5 Aduro BioTech Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Granulocyte Macrophage Colony Stimulating Factor Value Chain Analysis
  2. 9.1.1 Granulocyte Macrophage Colony Stimulating Factor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Granulocyte Macrophage Colony Stimulating Factor Production Mode & Process
  6. 9.2 Granulocyte Macrophage Colony Stimulating Factor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Granulocyte Macrophage Colony Stimulating Factor Distributors
  9. 9.2.3 Granulocyte Macrophage Colony Stimulating Factor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst